CytomX Therapeutics
CTMX
117 hedge funds and large institutions have $298M invested in CytomX Therapeutics in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 41 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6.03% more ownership
Funds ownership: 79.25% → 85.28% (+6%)
0% less capital invested
Capital invested by funds: $299M → $298M (-$1M)
10% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 41
2% less funds holding
Funds holding: 119 → 117 (-2)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$22M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$19M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.09M |
| 4 |
Renaissance Technologies
New York
|
+$1.01M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$974K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.52M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.85M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.98M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.87M |
| 5 |
Goldman Sachs
New York
|
-$1.83M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AGM
126
Alpine Global Management
New York
| – | -$273K | -32,895 | Closed |
|
|
AG
127
Algert Global
San Francisco,
California
| – | -$269K | -32,403 | Closed |
|
|
HF
128
HRT Financial
New York
| – | -$153K | -18,478 | Closed |
|
129
Capital Fund Management (CFM)
Paris,
France
| – | -$153K | -18,443 | Closed |
|
130
ProShare Advisors
Bethesda,
Maryland
| – | -$132K | -15,930 | Closed |
|
|
HS
131
HighVista Strategies
Boston,
Massachusetts
| – | -$116K | -13,900 | Closed |
|
132
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$47K | -5,630 | Closed |
|
|
TRCT
133
Tower Research Capital (TRC)
New York
| – | -$32K | -3,856 | Closed |
|
134
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$12K | -1,490 | Closed |
|
|
PHK
135
Point72 Hong Kong
Hong Kong
| – | -$9K | -1,135 | Closed |
|
|
II
136
Inspire Investing
Meridian,
Idaho
| – | +$370 | +53 | New |
|
CTMX Hedge Fund Activity: Q1 2020 in Review
117 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2020, worth a combined $298M — down 0.33% from $299M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CTMX and 17 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 37 added.
The largest buyer was BVF Inc, adding an estimated $22M. The largest seller was Point72 Asset Management, cutting an estimated $3.52M.
- 117 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2020, down from 119 in Q4 2019.
- Funds reported $298M of CytomX Therapeutics stock for Q1 2020, down 0.33% quarter-over-quarter.
- 17 funds opened new CytomX Therapeutics positions in Q1 2020 and 19 closed out, a net change of -2 holders.
- The largest CytomX Therapeutics buyer in Q1 2020 was BVF Inc, an estimated $22M added.
- The largest CytomX Therapeutics seller in Q1 2020 was Point72 Asset Management, an estimated $3.52M sold.
Based on aggregated 13F filings for Q1 2020.